isovitexin has been researched along with Cancer of Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, RL; He, JQ; Huang, P; Sun, CH; Wang, Z; Yu, CH; Yu, WY; Zhang, HH | 1 |
| Cao, J; Cao, X; Liu, F; Xia, L; Yuan, Q; Zhang, J | 1 |
2 other study(ies) available for isovitexin and Cancer of Lung
| Article | Year |
|---|---|
Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apigenin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytokines; Down-Regulation; Drug Synergism; Glucose; Humans; Killer Cells, Natural; Lactic Acid; Lung Neoplasms; Male; Membrane Proteins; Mice, Nude; T-Lymphocytes, Cytotoxic; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2021 |
Isovitexin Suppresses Stemness of Lung Cancer Stem-Like Cells through Blockage of MnSOD/CaMKII/AMPK Signaling and Glycolysis Inhibition.
Topics: A549 Cells; Adenylate Kinase; Animals; Apigenin; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Line, Tumor; Cell Survival; Glycolysis; Humans; Lactic Acid; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Signal Transduction; Superoxide Dismutase; Wound Healing | 2021 |